company_name,company_ticker,company_lei,company_cik,year,quarter,start_date,end_date,filing_date,parent,tag,financial_name,factor,balance,unit,value
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q1,2009-03-29,2009-06-27,2010-08-11 15:52:27+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,154087000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q1,2009-03-29,2009-06-27,2010-08-11 15:52:27+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,154087000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q1,2009-03-29,2009-06-27,2010-08-11 15:52:27+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,71144000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q1,2009-03-29,2009-06-27,2010-08-11 15:52:27+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,71144000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q1,2009-03-29,2009-06-27,2010-08-11 15:52:27+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,82943000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q1,2009-03-29,2009-06-27,2010-08-11 15:52:27+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,49839000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q1,2009-03-29,2009-06-27,2010-08-11 15:52:27+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6777000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q1,2009-03-29,2009-06-27,2010-08-11 15:52:27+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,56616000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q1,2009-03-29,2009-06-27,2010-08-11 15:52:27+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,26327000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q1,2009-03-29,2009-06-27,2010-08-11 15:52:27+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,214000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q1,2009-03-29,2009-06-27,2010-08-11 15:52:27+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,157000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q1,2009-03-29,2009-06-27,2010-08-11 15:52:27+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-335000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q1,2009-03-29,2009-06-27,2010-08-11 15:52:27+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-392000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q1,2009-03-29,2009-06-27,2010-08-11 15:52:27+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,25935000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q1,2009-03-29,2009-06-27,2010-08-11 15:52:27+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,7862000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q1,2009-03-29,2009-06-27,2010-08-11 15:52:27+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,18073000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q1,2009-03-29,2009-06-27,2010-08-11 15:52:27+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,18073000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q1,2009-03-29,2009-06-27,2010-08-11 15:52:27+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,18073000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q1,2009-03-29,2009-06-27,2010-08-11 15:52:27+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,25658000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q1,2009-03-29,2009-06-27,2010-08-11 15:52:27+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.7
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q1,2009-03-29,2009-06-27,2010-08-11 15:52:27+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,26201000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q1,2009-03-29,2009-06-27,2010-08-11 15:52:27+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.69
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q1,2009-03-29,2009-06-27,2010-08-11 15:52:27+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,25800000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q1,2009-03-29,2009-06-27,2010-08-11 15:52:27+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.7
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q2,2009-06-28,2009-09-26,2010-11-10 11:37:24+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,157070000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q2,2009-06-28,2009-09-26,2010-11-10 11:37:24+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,157070000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q2,2009-06-28,2009-09-26,2010-11-10 11:37:24+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,76103000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q2,2009-06-28,2009-09-26,2010-11-10 11:37:24+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,76103000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q2,2009-06-28,2009-09-26,2010-11-10 11:37:24+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,80967000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q2,2009-06-28,2009-09-26,2010-11-10 11:37:24+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,47469000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q2,2009-06-28,2009-09-26,2010-11-10 11:37:24+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6475000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q2,2009-06-28,2009-09-26,2010-11-10 11:37:24+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,0.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q2,2009-06-28,2009-09-26,2010-11-10 11:37:24+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,53944000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q2,2009-06-28,2009-09-26,2010-11-10 11:37:24+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,27023000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q2,2009-06-28,2009-09-26,2010-11-10 11:37:24+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,255000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q2,2009-06-28,2009-09-26,2010-11-10 11:37:24+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,103000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q2,2009-06-28,2009-09-26,2010-11-10 11:37:24+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-801000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q2,2009-06-28,2009-09-26,2010-11-10 11:37:24+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-953000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q2,2009-06-28,2009-09-26,2010-11-10 11:37:24+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,26070000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q2,2009-06-28,2009-09-26,2010-11-10 11:37:24+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,8020000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q2,2009-06-28,2009-09-26,2010-11-10 11:37:24+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,18050000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q2,2009-06-28,2009-09-26,2010-11-10 11:37:24+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,18050000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q2,2009-06-28,2009-09-26,2010-11-10 11:37:24+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,18050000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q2,2009-06-28,2009-09-26,2010-11-10 11:37:24+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,25685000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q2,2009-06-28,2009-09-26,2010-11-10 11:37:24+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.7
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q2,2009-06-28,2009-09-26,2010-11-10 11:37:24+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,26321000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q2,2009-06-28,2009-09-26,2010-11-10 11:37:24+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.69
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q2,2009-06-28,2009-09-26,2010-11-10 11:37:24+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,25800000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q2,2009-06-28,2009-09-26,2010-11-10 11:37:24+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.7
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q3,2009-09-27,2009-12-26,2011-02-08 17:01:20+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,165169000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q3,2009-09-27,2009-12-26,2011-02-08 17:01:20+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,165169000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q3,2009-09-27,2009-12-26,2011-02-08 17:01:20+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,79722000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q3,2009-09-27,2009-12-26,2011-02-08 17:01:20+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,79722000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q3,2009-09-27,2009-12-26,2011-02-08 17:01:20+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,85447000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q3,2009-09-27,2009-12-26,2011-02-08 17:01:20+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,53151000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q3,2009-09-27,2009-12-26,2011-02-08 17:01:20+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6461000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q3,2009-09-27,2009-12-26,2011-02-08 17:01:20+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,59612000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q3,2009-09-27,2009-12-26,2011-02-08 17:01:20+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,25835000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q3,2009-09-27,2009-12-26,2011-02-08 17:01:20+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,248000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q3,2009-09-27,2009-12-26,2011-02-08 17:01:20+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,56000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q3,2009-09-27,2009-12-26,2011-02-08 17:01:20+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-266000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q3,2009-09-27,2009-12-26,2011-02-08 17:01:20+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-458000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q3,2009-09-27,2009-12-26,2011-02-08 17:01:20+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,25377000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q3,2009-09-27,2009-12-26,2011-02-08 17:01:20+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,7091000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q3,2009-09-27,2009-12-26,2011-02-08 17:01:20+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,18286000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q3,2009-09-27,2009-12-26,2011-02-08 17:01:20+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,18286000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q3,2009-09-27,2009-12-26,2011-02-08 17:01:20+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,18286000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q3,2009-09-27,2009-12-26,2011-02-08 17:01:20+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,25289000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q3,2009-09-27,2009-12-26,2011-02-08 17:01:20+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.72
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q3,2009-09-27,2009-12-26,2011-02-08 17:01:20+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,25907000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q3,2009-09-27,2009-12-26,2011-02-08 17:01:20+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.71
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q3,2009-09-27,2009-12-26,2011-02-08 17:01:20+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,25400000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q3,2009-09-27,2009-12-26,2011-02-08 17:01:20+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.72
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q4,2009-12-27,2010-04-03,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,169104000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q4,2009-12-27,2010-04-03,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,169104000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q4,2009-12-27,2010-04-03,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,80980000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q4,2009-12-27,2010-04-03,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,80980000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q4,2009-12-27,2010-04-03,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,88124000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q4,2009-12-27,2010-04-03,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,64024000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q4,2009-12-27,2010-04-03,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,6663000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q4,2009-12-27,2010-04-03,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,-2345000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q4,2009-12-27,2010-04-03,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,15686000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q4,2009-12-27,2010-04-03,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,84028000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q4,2009-12-27,2010-04-03,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,4096000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q4,2009-12-27,2010-04-03,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,-717000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q4,2009-12-27,2010-04-03,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-316000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q4,2009-12-27,2010-04-03,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-608000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q4,2009-12-27,2010-04-03,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-207000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q4,2009-12-27,2010-04-03,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,3889000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q4,2009-12-27,2010-04-03,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-72000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q4,2009-12-27,2010-04-03,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,3961000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q4,2009-12-27,2010-04-03,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,3961000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q4,2009-12-27,2010-04-03,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,3961000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q4,2009-12-27,2010-04-03,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,25451000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q4,2009-12-27,2010-04-03,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.16
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q4,2009-12-27,2010-04-03,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,26063000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q4,2009-12-27,2010-04-03,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.16
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q4,2009-12-27,2010-04-03,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,25500000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2010.0,Q4,2009-12-27,2010-04-03,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.16
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q1,2010-04-04,2010-07-03,2011-08-10 09:52:57+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,163039000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q1,2010-04-04,2010-07-03,2011-08-10 09:52:57+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,163039000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q1,2010-04-04,2010-07-03,2011-08-10 09:52:57+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,76576000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q1,2010-04-04,2010-07-03,2011-08-10 09:52:57+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,76576000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q1,2010-04-04,2010-07-03,2011-08-10 09:52:57+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,86463000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q1,2010-04-04,2010-07-03,2011-08-10 09:52:57+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,54354000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q1,2010-04-04,2010-07-03,2011-08-10 09:52:57+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7920000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q1,2010-04-04,2010-07-03,2011-08-10 09:52:57+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,62274000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q1,2010-04-04,2010-07-03,2011-08-10 09:52:57+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,24189000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q1,2010-04-04,2010-07-03,2011-08-10 09:52:57+00:00,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,153000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q1,2010-04-04,2010-07-03,2011-08-10 09:52:57+00:00,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,102000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q1,2010-04-04,2010-07-03,2011-08-10 09:52:57+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,237000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q1,2010-04-04,2010-07-03,2011-08-10 09:52:57+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,186000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q1,2010-04-04,2010-07-03,2011-08-10 09:52:57+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,24375000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q1,2010-04-04,2010-07-03,2011-08-10 09:52:57+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,6457000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q1,2010-04-04,2010-07-03,2011-08-10 09:52:57+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,17918000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q1,2010-04-04,2010-07-03,2011-08-10 09:52:57+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,17918000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q1,2010-04-04,2010-07-03,2011-08-10 09:52:57+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,17918000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q1,2010-04-04,2010-07-03,2011-08-10 09:52:57+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,25140000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q1,2010-04-04,2010-07-03,2011-08-10 09:52:57+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.71
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q1,2010-04-04,2010-07-03,2011-08-10 09:52:57+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,25703000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q1,2010-04-04,2010-07-03,2011-08-10 09:52:57+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.7
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q1,2010-04-04,2010-07-03,2011-08-10 09:52:57+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,25200000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q1,2010-04-04,2010-07-03,2011-08-10 09:52:57+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.71
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q2,2010-07-04,2010-10-02,2011-11-03 16:22:41+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,166833000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q2,2010-07-04,2010-10-02,2011-11-03 16:22:41+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,166833000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q2,2010-07-04,2010-10-02,2011-11-03 16:22:41+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,79078000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q2,2010-07-04,2010-10-02,2011-11-03 16:22:41+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,79078000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q2,2010-07-04,2010-10-02,2011-11-03 16:22:41+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,87755000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q2,2010-07-04,2010-10-02,2011-11-03 16:22:41+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,52790000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q2,2010-07-04,2010-10-02,2011-11-03 16:22:41+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7954000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q2,2010-07-04,2010-10-02,2011-11-03 16:22:41+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,-1894000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q2,2010-07-04,2010-10-02,2011-11-03 16:22:41+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,58850000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q2,2010-07-04,2010-10-02,2011-11-03 16:22:41+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,28905000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q2,2010-07-04,2010-10-02,2011-11-03 16:22:41+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,254000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q2,2010-07-04,2010-10-02,2011-11-03 16:22:41+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,254000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q2,2010-07-04,2010-10-02,2011-11-03 16:22:41+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,29159000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q2,2010-07-04,2010-10-02,2011-11-03 16:22:41+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,7821000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q2,2010-07-04,2010-10-02,2011-11-03 16:22:41+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,21338000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q2,2010-07-04,2010-10-02,2011-11-03 16:22:41+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,21338000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q2,2010-07-04,2010-10-02,2011-11-03 16:22:41+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,21338000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q2,2010-07-04,2010-10-02,2011-11-03 16:22:41+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,24686000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q2,2010-07-04,2010-10-02,2011-11-03 16:22:41+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.86
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q2,2010-07-04,2010-10-02,2011-11-03 16:22:41+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,25228000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q2,2010-07-04,2010-10-02,2011-11-03 16:22:41+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.85
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q2,2010-07-04,2010-10-02,2011-11-03 16:22:41+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,24800000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q2,2010-07-04,2010-10-02,2011-11-03 16:22:41+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.86
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q3,2010-10-03,2011-01-01,2012-02-06 14:02:32+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,176789000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q3,2010-10-03,2011-01-01,2012-02-06 14:02:32+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,176789000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q3,2010-10-03,2011-01-01,2012-02-06 14:02:32+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,83299000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q3,2010-10-03,2011-01-01,2012-02-06 14:02:32+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,83299000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q3,2010-10-03,2011-01-01,2012-02-06 14:02:32+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,93490000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q3,2010-10-03,2011-01-01,2012-02-06 14:02:32+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,56935000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q3,2010-10-03,2011-01-01,2012-02-06 14:02:32+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7996000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q3,2010-10-03,2011-01-01,2012-02-06 14:02:32+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,0.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q3,2010-10-03,2011-01-01,2012-02-06 14:02:32+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,64931000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q3,2010-10-03,2011-01-01,2012-02-06 14:02:32+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,28559000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q3,2010-10-03,2011-01-01,2012-02-06 14:02:32+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-585000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q3,2010-10-03,2011-01-01,2012-02-06 14:02:32+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-585000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q3,2010-10-03,2011-01-01,2012-02-06 14:02:32+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,27974000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q3,2010-10-03,2011-01-01,2012-02-06 14:02:32+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,8240000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q3,2010-10-03,2011-01-01,2012-02-06 14:02:32+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,19734000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q3,2010-10-03,2011-01-01,2012-02-06 14:02:32+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,19734000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q3,2010-10-03,2011-01-01,2012-02-06 14:02:32+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,19734000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q3,2010-10-03,2011-01-01,2012-02-06 14:02:32+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,24973000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q3,2010-10-03,2011-01-01,2012-02-06 14:02:32+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.79
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q3,2010-10-03,2011-01-01,2012-02-06 14:02:32+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,25517000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q3,2010-10-03,2011-01-01,2012-02-06 14:02:32+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.77
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q3,2010-10-03,2011-01-01,2012-02-06 14:02:32+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,25000000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q3,2010-10-03,2011-01-01,2012-02-06 14:02:32+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.79
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q4,2011-01-02,2011-04-02,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,170033000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q4,2011-01-02,2011-04-02,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,170033000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q4,2011-01-02,2011-04-02,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,82532000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q4,2011-01-02,2011-04-02,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,82532000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q4,2011-01-02,2011-04-02,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,87501000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q4,2011-01-02,2011-04-02,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,49820000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q4,2011-01-02,2011-04-02,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8786000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q4,2011-01-02,2011-04-02,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,58606000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q4,2011-01-02,2011-04-02,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,28895000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q4,2011-01-02,2011-04-02,,totalotherincome,totalinterestexpense,Interest Expense,-,debit,usd,-153000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q4,2011-01-02,2011-04-02,,totalotherincome,totalinterestincome,Interest & Investment Income,+,credit,usd,-102000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q4,2011-01-02,2011-04-02,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-373000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q4,2011-01-02,2011-04-02,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-322000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q4,2011-01-02,2011-04-02,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,28573000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q4,2011-01-02,2011-04-02,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,7583000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q4,2011-01-02,2011-04-02,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,20990000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q4,2011-01-02,2011-04-02,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,20990000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q4,2011-01-02,2011-04-02,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,20990000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q4,2011-01-02,2011-04-02,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,50154000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q4,2011-01-02,2011-04-02,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.42
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q4,2011-01-02,2011-04-02,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,51192000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q4,2011-01-02,2011-04-02,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.42
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q4,2011-01-02,2011-04-02,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,50300000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2011.0,Q4,2011-01-02,2011-04-02,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.42
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q1,2011-04-03,2011-07-02,2012-08-08 16:52:55+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,170569000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q1,2011-04-03,2011-07-02,2012-08-08 16:52:55+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,170569000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q1,2011-04-03,2011-07-02,2012-08-08 16:52:55+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,81821000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q1,2011-04-03,2011-07-02,2012-08-08 16:52:55+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,81821000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q1,2011-04-03,2011-07-02,2012-08-08 16:52:55+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,88748000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q1,2011-04-03,2011-07-02,2012-08-08 16:52:55+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,56231000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q1,2011-04-03,2011-07-02,2012-08-08 16:52:55+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8609000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q1,2011-04-03,2011-07-02,2012-08-08 16:52:55+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,64840000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q1,2011-04-03,2011-07-02,2012-08-08 16:52:55+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,23908000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q1,2011-04-03,2011-07-02,2012-08-08 16:52:55+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-215000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q1,2011-04-03,2011-07-02,2012-08-08 16:52:55+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-215000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q1,2011-04-03,2011-07-02,2012-08-08 16:52:55+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,23693000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q1,2011-04-03,2011-07-02,2012-08-08 16:52:55+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,6746000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q1,2011-04-03,2011-07-02,2012-08-08 16:52:55+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,16947000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q1,2011-04-03,2011-07-02,2012-08-08 16:52:55+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,16947000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q1,2011-04-03,2011-07-02,2012-08-08 16:52:55+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,16947000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q1,2011-04-03,2011-07-02,2012-08-08 16:52:55+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,25731000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q1,2011-04-03,2011-07-02,2012-08-08 16:52:55+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.66
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q1,2011-04-03,2011-07-02,2012-08-08 16:52:55+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,26216000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q1,2011-04-03,2011-07-02,2012-08-08 16:52:55+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.65
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q1,2011-04-03,2011-07-02,2012-08-08 16:52:55+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,25700000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q1,2011-04-03,2011-07-02,2012-08-08 16:52:55+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.66
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q2,2011-07-03,2011-10-01,2012-11-07 17:24:19+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,179445000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q2,2011-07-03,2011-10-01,2012-11-07 17:24:19+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,179445000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q2,2011-07-03,2011-10-01,2012-11-07 17:24:19+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,89496000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q2,2011-07-03,2011-10-01,2012-11-07 17:24:19+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,89496000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q2,2011-07-03,2011-10-01,2012-11-07 17:24:19+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,89949000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q2,2011-07-03,2011-10-01,2012-11-07 17:24:19+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,62613000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q2,2011-07-03,2011-10-01,2012-11-07 17:24:19+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10350000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q2,2011-07-03,2011-10-01,2012-11-07 17:24:19+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,-1580000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q2,2011-07-03,2011-10-01,2012-11-07 17:24:19+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,71383000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q2,2011-07-03,2011-10-01,2012-11-07 17:24:19+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,18566000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q2,2011-07-03,2011-10-01,2012-11-07 17:24:19+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,445000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q2,2011-07-03,2011-10-01,2012-11-07 17:24:19+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,445000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q2,2011-07-03,2011-10-01,2012-11-07 17:24:19+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,19011000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q2,2011-07-03,2011-10-01,2012-11-07 17:24:19+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,5131000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q2,2011-07-03,2011-10-01,2012-11-07 17:24:19+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,13880000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q2,2011-07-03,2011-10-01,2012-11-07 17:24:19+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,13880000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q2,2011-07-03,2011-10-01,2012-11-07 17:24:19+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,13880000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q2,2011-07-03,2011-10-01,2012-11-07 17:24:19+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,25418000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q2,2011-07-03,2011-10-01,2012-11-07 17:24:19+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.55
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q2,2011-07-03,2011-10-01,2012-11-07 17:24:19+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,25843000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q2,2011-07-03,2011-10-01,2012-11-07 17:24:19+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.54
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q2,2011-07-03,2011-10-01,2012-11-07 17:24:19+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,25200000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q2,2011-07-03,2011-10-01,2012-11-07 17:24:19+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.55
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q3,2011-10-02,2011-12-31,2013-02-01 17:12:48+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,191160000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q3,2011-10-02,2011-12-31,2013-02-01 17:12:48+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,191160000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q3,2011-10-02,2011-12-31,2013-02-01 17:12:48+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,95229000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q3,2011-10-02,2011-12-31,2013-02-01 17:12:48+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,95229000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q3,2011-10-02,2011-12-31,2013-02-01 17:12:48+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,95931000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q3,2011-10-02,2011-12-31,2013-02-01 17:12:48+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,61376000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q3,2011-10-02,2011-12-31,2013-02-01 17:12:48+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,9232000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q3,2011-10-02,2011-12-31,2013-02-01 17:12:48+00:00,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,0.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q3,2011-10-02,2011-12-31,2013-02-01 17:12:48+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,70608000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q3,2011-10-02,2011-12-31,2013-02-01 17:12:48+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,25323000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q3,2011-10-02,2011-12-31,2013-02-01 17:12:48+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,140000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q3,2011-10-02,2011-12-31,2013-02-01 17:12:48+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,140000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q3,2011-10-02,2011-12-31,2013-02-01 17:12:48+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,25463000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q3,2011-10-02,2011-12-31,2013-02-01 17:12:48+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,7211000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q3,2011-10-02,2011-12-31,2013-02-01 17:12:48+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,18252000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q3,2011-10-02,2011-12-31,2013-02-01 17:12:48+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,18252000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q3,2011-10-02,2011-12-31,2013-02-01 17:12:48+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,18252000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q3,2011-10-02,2011-12-31,2013-02-01 17:12:48+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,50154000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q3,2011-10-02,2011-12-31,2013-02-01 17:12:48+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.36
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q3,2011-10-02,2011-12-31,2013-02-01 17:12:48+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,50876000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q3,2011-10-02,2011-12-31,2013-02-01 17:12:48+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.36
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q3,2011-10-02,2011-12-31,2013-02-01 17:12:48+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,50700000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q3,2011-10-02,2011-12-31,2013-02-01 17:12:48+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.36
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q4,2012-01-01,2012-03-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,186670000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q4,2012-01-01,2012-03-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,186670000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q4,2012-01-01,2012-03-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,92058000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q4,2012-01-01,2012-03-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,92058000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q4,2012-01-01,2012-03-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,94612000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q4,2012-01-01,2012-03-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,63461000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q4,2012-01-01,2012-03-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8610000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q4,2012-01-01,2012-03-31,,totaloperatingexpenses,otheroperatingexpenses,Other Operating Expenses / (Income),+,debit,usd,1580000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q4,2012-01-01,2012-03-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,73651000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q4,2012-01-01,2012-03-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,20961000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q4,2012-01-01,2012-03-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,370000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q4,2012-01-01,2012-03-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,370000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q4,2012-01-01,2012-03-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,21331000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q4,2012-01-01,2012-03-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,3524000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q4,2012-01-01,2012-03-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,17807000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q4,2012-01-01,2012-03-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,17807000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q4,2012-01-01,2012-03-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,17807000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q4,2012-01-01,2012-03-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,50727000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q4,2012-01-01,2012-03-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.35
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q4,2012-01-01,2012-03-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,51590000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q4,2012-01-01,2012-03-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.35
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q4,2012-01-01,2012-03-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,50700000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2012.0,Q4,2012-01-01,2012-03-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.35
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q1,2012-04-01,2012-06-30,2013-08-02 16:51:53+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,176475000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q1,2012-04-01,2012-06-30,2013-08-02 16:51:53+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,176475000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q1,2012-04-01,2012-06-30,2013-08-02 16:51:53+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,86362000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q1,2012-04-01,2012-06-30,2013-08-02 16:51:53+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,86362000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q1,2012-04-01,2012-06-30,2013-08-02 16:51:53+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,90113000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q1,2012-04-01,2012-06-30,2013-08-02 16:51:53+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,67625000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q1,2012-04-01,2012-06-30,2013-08-02 16:51:53+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,9409000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q1,2012-04-01,2012-06-30,2013-08-02 16:51:53+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,77034000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q1,2012-04-01,2012-06-30,2013-08-02 16:51:53+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,13079000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q1,2012-04-01,2012-06-30,2013-08-02 16:51:53+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,336000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q1,2012-04-01,2012-06-30,2013-08-02 16:51:53+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,336000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q1,2012-04-01,2012-06-30,2013-08-02 16:51:53+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,13415000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q1,2012-04-01,2012-06-30,2013-08-02 16:51:53+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,3628000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q1,2012-04-01,2012-06-30,2013-08-02 16:51:53+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,9787000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q1,2012-04-01,2012-06-30,2013-08-02 16:51:53+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,9787000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q1,2012-04-01,2012-06-30,2013-08-02 16:51:53+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,9787000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q1,2012-04-01,2012-06-30,2013-08-02 16:51:53+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,50966000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q1,2012-04-01,2012-06-30,2013-08-02 16:51:53+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.19
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q1,2012-04-01,2012-06-30,2013-08-02 16:51:53+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,51864000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q1,2012-04-01,2012-06-30,2013-08-02 16:51:53+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.19
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q1,2012-04-01,2012-06-30,2013-08-02 16:51:53+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,51500000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q1,2012-04-01,2012-06-30,2013-08-02 16:51:53+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.19
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q2,2012-07-01,2012-09-29,2013-10-30 17:00:03+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,218178000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q2,2012-07-01,2012-09-29,2013-10-30 17:00:03+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,218178000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q2,2012-07-01,2012-09-29,2013-10-30 17:00:03+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,116416000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q2,2012-07-01,2012-09-29,2013-10-30 17:00:03+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,116416000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q2,2012-07-01,2012-09-29,2013-10-30 17:00:03+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,101762000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q2,2012-07-01,2012-09-29,2013-10-30 17:00:03+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,81034000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q2,2012-07-01,2012-09-29,2013-10-30 17:00:03+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10827000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q2,2012-07-01,2012-09-29,2013-10-30 17:00:03+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,91861000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q2,2012-07-01,2012-09-29,2013-10-30 17:00:03+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,9901000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q2,2012-07-01,2012-09-29,2013-10-30 17:00:03+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1311000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q2,2012-07-01,2012-09-29,2013-10-30 17:00:03+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1311000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q2,2012-07-01,2012-09-29,2013-10-30 17:00:03+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,8590000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q2,2012-07-01,2012-09-29,2013-10-30 17:00:03+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,2043000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q2,2012-07-01,2012-09-29,2013-10-30 17:00:03+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,6547000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q2,2012-07-01,2012-09-29,2013-10-30 17:00:03+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,6547000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q2,2012-07-01,2012-09-29,2013-10-30 17:00:03+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,6547000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q2,2012-07-01,2012-09-29,2013-10-30 17:00:03+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,51420000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q2,2012-07-01,2012-09-29,2013-10-30 17:00:03+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.13
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q2,2012-07-01,2012-09-29,2013-10-30 17:00:03+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,52314000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q2,2012-07-01,2012-09-29,2013-10-30 17:00:03+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.13
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q2,2012-07-01,2012-09-29,2013-10-30 17:00:03+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,50400000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q2,2012-07-01,2012-09-29,2013-10-30 17:00:03+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.13
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q3,2012-09-30,2012-12-29,2014-01-30 17:06:58+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,247395000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q3,2012-09-30,2012-12-29,2014-01-30 17:06:58+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,247395000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q3,2012-09-30,2012-12-29,2014-01-30 17:06:58+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,134280000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q3,2012-09-30,2012-12-29,2014-01-30 17:06:58+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,134280000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q3,2012-09-30,2012-12-29,2014-01-30 17:06:58+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,113115000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q3,2012-09-30,2012-12-29,2014-01-30 17:06:58+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,86780000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q3,2012-09-30,2012-12-29,2014-01-30 17:06:58+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10588000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q3,2012-09-30,2012-12-29,2014-01-30 17:06:58+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,97368000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q3,2012-09-30,2012-12-29,2014-01-30 17:06:58+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,15747000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q3,2012-09-30,2012-12-29,2014-01-30 17:06:58+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-2542000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q3,2012-09-30,2012-12-29,2014-01-30 17:06:58+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2542000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q3,2012-09-30,2012-12-29,2014-01-30 17:06:58+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,13205000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q3,2012-09-30,2012-12-29,2014-01-30 17:06:58+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,3301000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q3,2012-09-30,2012-12-29,2014-01-30 17:06:58+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,9904000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q3,2012-09-30,2012-12-29,2014-01-30 17:06:58+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,9904000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q3,2012-09-30,2012-12-29,2014-01-30 17:06:58+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,9904000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q3,2012-09-30,2012-12-29,2014-01-30 17:06:58+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,51707000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q3,2012-09-30,2012-12-29,2014-01-30 17:06:58+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.19
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q3,2012-09-30,2012-12-29,2014-01-30 17:06:58+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,52606000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q3,2012-09-30,2012-12-29,2014-01-30 17:06:58+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.19
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q3,2012-09-30,2012-12-29,2014-01-30 17:06:58+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,52100000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q3,2012-09-30,2012-12-29,2014-01-30 17:06:58+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.19
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q4,2012-12-30,2013-03-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,249942000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q4,2012-12-30,2013-03-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,249942000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q4,2012-12-30,2013-03-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,126801000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q4,2012-12-30,2013-03-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,126801000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q4,2012-12-30,2013-03-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,123141000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q4,2012-12-30,2013-03-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,87614000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q4,2012-12-30,2013-03-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,13570000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q4,2012-12-30,2013-03-30,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,4247000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q4,2012-12-30,2013-03-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,105431000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q4,2012-12-30,2013-03-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,17710000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q4,2012-12-30,2013-03-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-3023000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q4,2012-12-30,2013-03-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-3023000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q4,2012-12-30,2013-03-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,14687000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q4,2012-12-30,2013-03-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,2125000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q4,2012-12-30,2013-03-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,12562000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q4,2012-12-30,2013-03-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,12562000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q4,2012-12-30,2013-03-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,12562000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q4,2012-12-30,2013-03-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,51349000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q4,2012-12-30,2013-03-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.24
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q4,2012-12-30,2013-03-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,52259000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q4,2012-12-30,2013-03-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.24
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q4,2012-12-30,2013-03-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,51100000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2013.0,Q4,2012-12-30,2013-03-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.24
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q1,2013-03-31,2013-06-29,2014-07-31 13:03:14+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,219543000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q1,2013-03-31,2013-06-29,2014-07-31 13:03:14+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,219543000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q1,2013-03-31,2013-06-29,2014-07-31 13:03:14+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,108131000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q1,2013-03-31,2013-06-29,2014-07-31 13:03:14+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,108131000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q1,2013-03-31,2013-06-29,2014-07-31 13:03:14+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,111412000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q1,2013-03-31,2013-06-29,2014-07-31 13:03:14+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,106811000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q1,2013-03-31,2013-06-29,2014-07-31 13:03:14+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,11209000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q1,2013-03-31,2013-06-29,2014-07-31 13:03:14+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,118020000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q1,2013-03-31,2013-06-29,2014-07-31 13:03:14+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-6608000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q1,2013-03-31,2013-06-29,2014-07-31 13:03:14+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-2641000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q1,2013-03-31,2013-06-29,2014-07-31 13:03:14+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2641000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q1,2013-03-31,2013-06-29,2014-07-31 13:03:14+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-9249000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q1,2013-03-31,2013-06-29,2014-07-31 13:03:14+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-1375000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q1,2013-03-31,2013-06-29,2014-07-31 13:03:14+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-7874000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q1,2013-03-31,2013-06-29,2014-07-31 13:03:14+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-7874000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q1,2013-03-31,2013-06-29,2014-07-31 13:03:14+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-7874000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q1,2013-03-31,2013-06-29,2014-07-31 13:03:14+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,51231000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q1,2013-03-31,2013-06-29,2014-07-31 13:03:14+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.15
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q1,2013-03-31,2013-06-29,2014-07-31 13:03:14+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,51231000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q1,2013-03-31,2013-06-29,2014-07-31 13:03:14+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.15
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q1,2013-03-31,2013-06-29,2014-07-31 13:03:14+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,52500000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q1,2013-03-31,2013-06-29,2014-07-31 13:03:14+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.15
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q2,2013-06-30,2013-09-28,2014-11-04 15:54:49+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,235755000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q2,2013-06-30,2013-09-28,2014-11-04 15:54:49+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,235755000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q2,2013-06-30,2013-09-28,2014-11-04 15:54:49+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,115871000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q2,2013-06-30,2013-09-28,2014-11-04 15:54:49+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,115871000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q2,2013-06-30,2013-09-28,2014-11-04 15:54:49+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,119884000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q2,2013-06-30,2013-09-28,2014-11-04 15:54:49+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,81508000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q2,2013-06-30,2013-09-28,2014-11-04 15:54:49+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,14946000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q2,2013-06-30,2013-09-28,2014-11-04 15:54:49+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,96454000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q2,2013-06-30,2013-09-28,2014-11-04 15:54:49+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,23430000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q2,2013-06-30,2013-09-28,2014-11-04 15:54:49+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-2542000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q2,2013-06-30,2013-09-28,2014-11-04 15:54:49+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2542000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q2,2013-06-30,2013-09-28,2014-11-04 15:54:49+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,20888000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q2,2013-06-30,2013-09-28,2014-11-04 15:54:49+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,4340000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q2,2013-06-30,2013-09-28,2014-11-04 15:54:49+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,16548000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q2,2013-06-30,2013-09-28,2014-11-04 15:54:49+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,16548000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q2,2013-06-30,2013-09-28,2014-11-04 15:54:49+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,16548000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q2,2013-06-30,2013-09-28,2014-11-04 15:54:49+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,51492000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q2,2013-06-30,2013-09-28,2014-11-04 15:54:49+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.32
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q2,2013-06-30,2013-09-28,2014-11-04 15:54:49+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,52361000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q2,2013-06-30,2013-09-28,2014-11-04 15:54:49+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.32
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q2,2013-06-30,2013-09-28,2014-11-04 15:54:49+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,51700000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q2,2013-06-30,2013-09-28,2014-11-04 15:54:49+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.32
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q3,2013-09-29,2013-12-28,2015-02-05 14:37:05+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,242120000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q3,2013-09-29,2013-12-28,2015-02-05 14:37:05+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,242120000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q3,2013-09-29,2013-12-28,2015-02-05 14:37:05+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,120491000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q3,2013-09-29,2013-12-28,2015-02-05 14:37:05+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,120491000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q3,2013-09-29,2013-12-28,2015-02-05 14:37:05+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,121629000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q3,2013-09-29,2013-12-28,2015-02-05 14:37:05+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,89560000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q3,2013-09-29,2013-12-28,2015-02-05 14:37:05+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,14209000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q3,2013-09-29,2013-12-28,2015-02-05 14:37:05+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,103769000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q3,2013-09-29,2013-12-28,2015-02-05 14:37:05+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,17860000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q3,2013-09-29,2013-12-28,2015-02-05 14:37:05+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-2852000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q3,2013-09-29,2013-12-28,2015-02-05 14:37:05+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2852000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q3,2013-09-29,2013-12-28,2015-02-05 14:37:05+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,15008000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q3,2013-09-29,2013-12-28,2015-02-05 14:37:05+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-1282000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q3,2013-09-29,2013-12-28,2015-02-05 14:37:05+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,16290000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q3,2013-09-29,2013-12-28,2015-02-05 14:37:05+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,16290000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q3,2013-09-29,2013-12-28,2015-02-05 14:37:05+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,16290000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q3,2013-09-29,2013-12-28,2015-02-05 14:37:05+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,51730000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q3,2013-09-29,2013-12-28,2015-02-05 14:37:05+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.31
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q3,2013-09-29,2013-12-28,2015-02-05 14:37:05+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,52511000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q3,2013-09-29,2013-12-28,2015-02-05 14:37:05+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.31
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q3,2013-09-29,2013-12-28,2015-02-05 14:37:05+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,52500000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q3,2013-09-29,2013-12-28,2015-02-05 14:37:05+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.31
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q4,2013-12-29,2014-03-29,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,241091000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q4,2013-12-29,2014-03-29,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,241091000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q4,2013-12-29,2014-03-29,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,125651000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q4,2013-12-29,2014-03-29,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,125651000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q4,2013-12-29,2014-03-29,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,115440000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q4,2013-12-29,2014-03-29,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,88143000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q4,2013-12-29,2014-03-29,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,13836000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q4,2013-12-29,2014-03-29,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,1711000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q4,2013-12-29,2014-03-29,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,103690000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q4,2013-12-29,2014-03-29,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,11750000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q4,2013-12-29,2014-03-29,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1996000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q4,2013-12-29,2014-03-29,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1996000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q4,2013-12-29,2014-03-29,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,9754000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q4,2013-12-29,2014-03-29,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-430000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q4,2013-12-29,2014-03-29,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,10184000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q4,2013-12-29,2014-03-29,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,10184000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q4,2013-12-29,2014-03-29,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,10184000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q4,2013-12-29,2014-03-29,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,51611000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q4,2013-12-29,2014-03-29,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.2
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q4,2013-12-29,2014-03-29,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,52377000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q4,2013-12-29,2014-03-29,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.2
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q4,2013-12-29,2014-03-29,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,51700000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2014.0,Q4,2013-12-29,2014-03-29,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.2
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q1,2014-03-30,2014-06-28,2015-07-30 16:32:19+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,224488000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q1,2014-03-30,2014-06-28,2015-07-30 16:32:19+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,224488000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q1,2014-03-30,2014-06-28,2015-07-30 16:32:19+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,118210000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q1,2014-03-30,2014-06-28,2015-07-30 16:32:19+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,118210000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q1,2014-03-30,2014-06-28,2015-07-30 16:32:19+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,106278000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q1,2014-03-30,2014-06-28,2015-07-30 16:32:19+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,92562000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q1,2014-03-30,2014-06-28,2015-07-30 16:32:19+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,15382000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q1,2014-03-30,2014-06-28,2015-07-30 16:32:19+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,107944000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q1,2014-03-30,2014-06-28,2015-07-30 16:32:19+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-1666000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q1,2014-03-30,2014-06-28,2015-07-30 16:32:19+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-2543000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q1,2014-03-30,2014-06-28,2015-07-30 16:32:19+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2543000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q1,2014-03-30,2014-06-28,2015-07-30 16:32:19+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-4209000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q1,2014-03-30,2014-06-28,2015-07-30 16:32:19+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-560000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q1,2014-03-30,2014-06-28,2015-07-30 16:32:19+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-3649000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q1,2014-03-30,2014-06-28,2015-07-30 16:32:19+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-3649000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q1,2014-03-30,2014-06-28,2015-07-30 16:32:19+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-3649000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q1,2014-03-30,2014-06-28,2015-07-30 16:32:19+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,51741000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q1,2014-03-30,2014-06-28,2015-07-30 16:32:19+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.07
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q1,2014-03-30,2014-06-28,2015-07-30 16:32:19+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,51741000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q1,2014-03-30,2014-06-28,2015-07-30 16:32:19+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.07
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q1,2014-03-30,2014-06-28,2015-07-30 16:32:19+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,52100000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q1,2014-03-30,2014-06-28,2015-07-30 16:32:19+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.07
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q2,2014-06-29,2014-09-27,2015-11-04 16:22:29+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,227580000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q2,2014-06-29,2014-09-27,2015-11-04 16:22:29+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,227580000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q2,2014-06-29,2014-09-27,2015-11-04 16:22:29+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,119466000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q2,2014-06-29,2014-09-27,2015-11-04 16:22:29+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,119466000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q2,2014-06-29,2014-09-27,2015-11-04 16:22:29+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,108114000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q2,2014-06-29,2014-09-27,2015-11-04 16:22:29+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,84769000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q2,2014-06-29,2014-09-27,2015-11-04 16:22:29+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10938000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q2,2014-06-29,2014-09-27,2015-11-04 16:22:29+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,95707000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q2,2014-06-29,2014-09-27,2015-11-04 16:22:29+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,12407000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q2,2014-06-29,2014-09-27,2015-11-04 16:22:29+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-2645000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q2,2014-06-29,2014-09-27,2015-11-04 16:22:29+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2645000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q2,2014-06-29,2014-09-27,2015-11-04 16:22:29+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,9762000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q2,2014-06-29,2014-09-27,2015-11-04 16:22:29+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,2275000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q2,2014-06-29,2014-09-27,2015-11-04 16:22:29+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,7487000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q2,2014-06-29,2014-09-27,2015-11-04 16:22:29+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,7487000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q2,2014-06-29,2014-09-27,2015-11-04 16:22:29+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,7487000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q2,2014-06-29,2014-09-27,2015-11-04 16:22:29+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,51391000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q2,2014-06-29,2014-09-27,2015-11-04 16:22:29+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.15
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q2,2014-06-29,2014-09-27,2015-11-04 16:22:29+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,51925000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q2,2014-06-29,2014-09-27,2015-11-04 16:22:29+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.14
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q2,2014-06-29,2014-09-27,2015-11-04 16:22:29+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,49900000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q2,2014-06-29,2014-09-27,2015-11-04 16:22:29+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.15
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q3,2014-09-28,2014-12-27,2016-02-02 16:04:13+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,231827000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q3,2014-09-28,2014-12-27,2016-02-02 16:04:13+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,231827000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q3,2014-09-28,2014-12-27,2016-02-02 16:04:13+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,120166000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q3,2014-09-28,2014-12-27,2016-02-02 16:04:13+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,120166000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q3,2014-09-28,2014-12-27,2016-02-02 16:04:13+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,111661000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q3,2014-09-28,2014-12-27,2016-02-02 16:04:13+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,82512000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q3,2014-09-28,2014-12-27,2016-02-02 16:04:13+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10643000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q3,2014-09-28,2014-12-27,2016-02-02 16:04:13+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q3,2014-09-28,2014-12-27,2016-02-02 16:04:13+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,246000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q3,2014-09-28,2014-12-27,2016-02-02 16:04:13+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,93401000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q3,2014-09-28,2014-12-27,2016-02-02 16:04:13+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,18260000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q3,2014-09-28,2014-12-27,2016-02-02 16:04:13+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-2308000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q3,2014-09-28,2014-12-27,2016-02-02 16:04:13+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2308000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q3,2014-09-28,2014-12-27,2016-02-02 16:04:13+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,15952000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q3,2014-09-28,2014-12-27,2016-02-02 16:04:13+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-36000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q3,2014-09-28,2014-12-27,2016-02-02 16:04:13+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,15988000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q3,2014-09-28,2014-12-27,2016-02-02 16:04:13+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,15988000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q3,2014-09-28,2014-12-27,2016-02-02 16:04:13+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,15988000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q3,2014-09-28,2014-12-27,2016-02-02 16:04:13+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,51432000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q3,2014-09-28,2014-12-27,2016-02-02 16:04:13+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.31
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q3,2014-09-28,2014-12-27,2016-02-02 16:04:13+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,51962000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q3,2014-09-28,2014-12-27,2016-02-02 16:04:13+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.31
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q3,2014-09-28,2014-12-27,2016-02-02 16:04:13+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,51600000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q3,2014-09-28,2014-12-27,2016-02-02 16:04:13+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.31
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q4,2014-12-28,2015-03-28,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,226478000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q4,2014-12-28,2015-03-28,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,226478000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q4,2014-12-28,2015-03-28,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,118113000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q4,2014-12-28,2015-03-28,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,118113000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q4,2014-12-28,2015-03-28,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,108365000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q4,2014-12-28,2015-03-28,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,77325000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q4,2014-12-28,2015-03-28,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,17224000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q4,2014-12-28,2015-03-28,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,5441000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q4,2014-12-28,2015-03-28,,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,-3164000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q4,2014-12-28,2015-03-28,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,96826000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q4,2014-12-28,2015-03-28,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,11539000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q4,2014-12-28,2015-03-28,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1879000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q4,2014-12-28,2015-03-28,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1879000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q4,2014-12-28,2015-03-28,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,9660000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q4,2014-12-28,2015-03-28,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,12589000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q4,2014-12-28,2015-03-28,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-2929000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q4,2014-12-28,2015-03-28,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-2929000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q4,2014-12-28,2015-03-28,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-2929000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q4,2014-12-28,2015-03-28,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,51533000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q4,2014-12-28,2015-03-28,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.06
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q4,2014-12-28,2015-03-28,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,52089000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q4,2014-12-28,2015-03-28,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.06
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q4,2014-12-28,2015-03-28,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,51200000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2015.0,Q4,2014-12-28,2015-03-28,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.06
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q1,2015-03-29,2015-06-27,2016-08-01 16:02:44+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,213413000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q1,2015-03-29,2015-06-27,2016-08-01 16:02:44+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,213413000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q1,2015-03-29,2015-06-27,2016-08-01 16:02:44+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,110874000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q1,2015-03-29,2015-06-27,2016-08-01 16:02:44+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,110874000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q1,2015-03-29,2015-06-27,2016-08-01 16:02:44+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,102539000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q1,2015-03-29,2015-06-27,2016-08-01 16:02:44+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,87612000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q1,2015-03-29,2015-06-27,2016-08-01 16:02:44+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,11321000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q1,2015-03-29,2015-06-27,2016-08-01 16:02:44+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,98933000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q1,2015-03-29,2015-06-27,2016-08-01 16:02:44+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,3606000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q1,2015-03-29,2015-06-27,2016-08-01 16:02:44+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-2009000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q1,2015-03-29,2015-06-27,2016-08-01 16:02:44+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2009000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q1,2015-03-29,2015-06-27,2016-08-01 16:02:44+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,1597000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q1,2015-03-29,2015-06-27,2016-08-01 16:02:44+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1864000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q1,2015-03-29,2015-06-27,2016-08-01 16:02:44+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-267000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q1,2015-03-29,2015-06-27,2016-08-01 16:02:44+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-267000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q1,2015-03-29,2015-06-27,2016-08-01 16:02:44+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-267000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q1,2015-03-29,2015-06-27,2016-08-01 16:02:44+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,51360000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q1,2015-03-29,2015-06-27,2016-08-01 16:02:44+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.01
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q1,2015-03-29,2015-06-27,2016-08-01 16:02:44+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,51360000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q1,2015-03-29,2015-06-27,2016-08-01 16:02:44+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.01
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q1,2015-03-29,2015-06-27,2016-08-01 16:02:44+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,26700000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q1,2015-03-29,2015-06-27,2016-08-01 16:02:44+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.01
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q2,2015-06-28,2015-09-26,2016-11-07 16:06:04+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,219693000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q2,2015-06-28,2015-09-26,2016-11-07 16:06:04+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,219693000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q2,2015-06-28,2015-09-26,2016-11-07 16:06:04+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,114396000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q2,2015-06-28,2015-09-26,2016-11-07 16:06:04+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,114396000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q2,2015-06-28,2015-09-26,2016-11-07 16:06:04+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,105297000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q2,2015-06-28,2015-09-26,2016-11-07 16:06:04+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,74565000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q2,2015-06-28,2015-09-26,2016-11-07 16:06:04+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,11553000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q2,2015-06-28,2015-09-26,2016-11-07 16:06:04+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,86118000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q2,2015-06-28,2015-09-26,2016-11-07 16:06:04+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,19179000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q2,2015-06-28,2015-09-26,2016-11-07 16:06:04+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-2606000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q2,2015-06-28,2015-09-26,2016-11-07 16:06:04+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2606000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q2,2015-06-28,2015-09-26,2016-11-07 16:06:04+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,16573000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q2,2015-06-28,2015-09-26,2016-11-07 16:06:04+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,3700000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q2,2015-06-28,2015-09-26,2016-11-07 16:06:04+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,12873000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q2,2015-06-28,2015-09-26,2016-11-07 16:06:04+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,12863000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q2,2015-06-28,2015-09-26,2016-11-07 16:06:04+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,12863000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q2,2015-06-28,2015-09-26,2016-11-07 16:06:04+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,50680000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q2,2015-06-28,2015-09-26,2016-11-07 16:06:04+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.25
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q2,2015-06-28,2015-09-26,2016-11-07 16:06:04+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,51187000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q2,2015-06-28,2015-09-26,2016-11-07 16:06:04+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.25
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q2,2015-06-28,2015-09-26,2016-11-07 16:06:04+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,51500000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q2,2015-06-28,2015-09-26,2016-11-07 16:06:04+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.25
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q3,2015-09-27,2015-12-26,2017-02-06 16:06:56+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,233384000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q3,2015-09-27,2015-12-26,2017-02-06 16:06:56+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,233384000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q3,2015-09-27,2015-12-26,2017-02-06 16:06:56+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,124529000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q3,2015-09-27,2015-12-26,2017-02-06 16:06:56+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,124529000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q3,2015-09-27,2015-12-26,2017-02-06 16:06:56+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,108855000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q3,2015-09-27,2015-12-26,2017-02-06 16:06:56+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,78940000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q3,2015-09-27,2015-12-26,2017-02-06 16:06:56+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,10942000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q3,2015-09-27,2015-12-26,2017-02-06 16:06:56+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,85048000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q3,2015-09-27,2015-12-26,2017-02-06 16:06:56+00:00,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,-4898000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q3,2015-09-27,2015-12-26,2017-02-06 16:06:56+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,170032000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q3,2015-09-27,2015-12-26,2017-02-06 16:06:56+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-61177000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q3,2015-09-27,2015-12-26,2017-02-06 16:06:56+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-2141000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q3,2015-09-27,2015-12-26,2017-02-06 16:06:56+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2141000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q3,2015-09-27,2015-12-26,2017-02-06 16:06:56+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-63318000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q3,2015-09-27,2015-12-26,2017-02-06 16:06:56+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-3878000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q3,2015-09-27,2015-12-26,2017-02-06 16:06:56+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-59440000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q3,2015-09-27,2015-12-26,2017-02-06 16:06:56+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-59440000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q3,2015-09-27,2015-12-26,2017-02-06 16:06:56+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-59440000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q3,2015-09-27,2015-12-26,2017-02-06 16:06:56+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,50741000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q3,2015-09-27,2015-12-26,2017-02-06 16:06:56+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.17
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q3,2015-09-27,2015-12-26,2017-02-06 16:06:56+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,50741000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q3,2015-09-27,2015-12-26,2017-02-06 16:06:56+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-1.17
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q3,2015-09-27,2015-12-26,2017-02-06 16:06:56+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,50800000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q3,2015-09-27,2015-12-26,2017-02-06 16:06:56+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.17
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q4,2015-12-27,2016-04-02,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,242342000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q4,2015-12-27,2016-04-02,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,242342000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q4,2015-12-27,2016-04-02,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,153119000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q4,2015-12-27,2016-04-02,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,153119000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q4,2015-12-27,2016-04-02,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,89223000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q4,2015-12-27,2016-04-02,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,76106000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q4,2015-12-27,2016-04-02,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,11149000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q4,2015-12-27,2016-04-02,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,7347000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q4,2015-12-27,2016-04-02,,totaloperatingexpenses,otherspecialcharges,Other Special Charges / (Income),+,debit,usd,171000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q4,2015-12-27,2016-04-02,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,94773000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q4,2015-12-27,2016-04-02,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-5550000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q4,2015-12-27,2016-04-02,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-2718000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q4,2015-12-27,2016-04-02,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2718000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q4,2015-12-27,2016-04-02,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-8268000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q4,2015-12-27,2016-04-02,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,477000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q4,2015-12-27,2016-04-02,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-8745000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q4,2015-12-27,2016-04-02,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-8735000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q4,2015-12-27,2016-04-02,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-8735000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q4,2015-12-27,2016-04-02,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,50910000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q4,2015-12-27,2016-04-02,,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.16
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q4,2015-12-27,2016-04-02,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,50910000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q4,2015-12-27,2016-04-02,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.16
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q4,2015-12-27,2016-04-02,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,51000000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2016.0,Q4,2015-12-27,2016-04-02,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.16
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q1,2016-04-03,2016-07-02,2017-08-07 16:28:17+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,209956000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q1,2016-04-03,2016-07-02,2017-08-07 16:28:17+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,209956000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q1,2016-04-03,2016-07-02,2017-08-07 16:28:17+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,118900000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q1,2016-04-03,2016-07-02,2017-08-07 16:28:17+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,118900000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q1,2016-04-03,2016-07-02,2017-08-07 16:28:17+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,91056000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q1,2016-04-03,2016-07-02,2017-08-07 16:28:17+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,87500000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q1,2016-04-03,2016-07-02,2017-08-07 16:28:17+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,11437000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q1,2016-04-03,2016-07-02,2017-08-07 16:28:17+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,98937000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q1,2016-04-03,2016-07-02,2017-08-07 16:28:17+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-7881000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q1,2016-04-03,2016-07-02,2017-08-07 16:28:17+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-2177000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q1,2016-04-03,2016-07-02,2017-08-07 16:28:17+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2177000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q1,2016-04-03,2016-07-02,2017-08-07 16:28:17+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-10058000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q1,2016-04-03,2016-07-02,2017-08-07 16:28:17+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,288000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q1,2016-04-03,2016-07-02,2017-08-07 16:28:17+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-10346000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q1,2016-04-03,2016-07-02,2017-08-07 16:28:17+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-10346000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q1,2016-04-03,2016-07-02,2017-08-07 16:28:17+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-10346000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q1,2016-04-03,2016-07-02,2017-08-07 16:28:17+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,51021000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q1,2016-04-03,2016-07-02,2017-08-07 16:28:17+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.2
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q1,2016-04-03,2016-07-02,2017-08-07 16:28:17+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,51021000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q1,2016-04-03,2016-07-02,2017-08-07 16:28:17+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.2
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q1,2016-04-03,2016-07-02,2017-08-07 16:28:17+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,51700000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q1,2016-04-03,2016-07-02,2017-08-07 16:28:17+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.2
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q2,2016-07-03,2016-10-01,2017-11-07 16:03:28+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,220253000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q2,2016-07-03,2016-10-01,2017-11-07 16:03:28+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,220253000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q2,2016-07-03,2016-10-01,2017-11-07 16:03:28+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,116005000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q2,2016-07-03,2016-10-01,2017-11-07 16:03:28+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,116005000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q2,2016-07-03,2016-10-01,2017-11-07 16:03:28+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,104248000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q2,2016-07-03,2016-10-01,2017-11-07 16:03:28+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,71118000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q2,2016-07-03,2016-10-01,2017-11-07 16:03:28+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8336000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q2,2016-07-03,2016-10-01,2017-11-07 16:03:28+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,79454000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q2,2016-07-03,2016-10-01,2017-11-07 16:03:28+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,24794000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q2,2016-07-03,2016-10-01,2017-11-07 16:03:28+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1962000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q2,2016-07-03,2016-10-01,2017-11-07 16:03:28+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1962000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q2,2016-07-03,2016-10-01,2017-11-07 16:03:28+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,22832000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q2,2016-07-03,2016-10-01,2017-11-07 16:03:28+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,3007000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q2,2016-07-03,2016-10-01,2017-11-07 16:03:28+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,19825000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q2,2016-07-03,2016-10-01,2017-11-07 16:03:28+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,19825000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q2,2016-07-03,2016-10-01,2017-11-07 16:03:28+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,19825000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q2,2016-07-03,2016-10-01,2017-11-07 16:03:28+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,51378000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q2,2016-07-03,2016-10-01,2017-11-07 16:03:28+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.39
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q2,2016-07-03,2016-10-01,2017-11-07 16:03:28+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,51701000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q2,2016-07-03,2016-10-01,2017-11-07 16:03:28+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.38
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q2,2016-07-03,2016-10-01,2017-11-07 16:03:28+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,50800000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q2,2016-07-03,2016-10-01,2017-11-07 16:03:28+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.39
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q3,2016-10-02,2016-12-31,2018-02-06 16:55:24+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,227841000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q3,2016-10-02,2016-12-31,2018-02-06 16:55:24+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,227841000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q3,2016-10-02,2016-12-31,2018-02-06 16:55:24+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,126762000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q3,2016-10-02,2016-12-31,2018-02-06 16:55:24+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,126762000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q3,2016-10-02,2016-12-31,2018-02-06 16:55:24+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,101079000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q3,2016-10-02,2016-12-31,2018-02-06 16:55:24+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,71405000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q3,2016-10-02,2016-12-31,2018-02-06 16:55:24+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8462000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q3,2016-10-02,2016-12-31,2018-02-06 16:55:24+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,79867000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q3,2016-10-02,2016-12-31,2018-02-06 16:55:24+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,21212000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q3,2016-10-02,2016-12-31,2018-02-06 16:55:24+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-2275000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q3,2016-10-02,2016-12-31,2018-02-06 16:55:24+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2275000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q3,2016-10-02,2016-12-31,2018-02-06 16:55:24+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,18937000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q3,2016-10-02,2016-12-31,2018-02-06 16:55:24+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,3500000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q3,2016-10-02,2016-12-31,2018-02-06 16:55:24+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,15437000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q3,2016-10-02,2016-12-31,2018-02-06 16:55:24+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,15393000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q3,2016-10-02,2016-12-31,2018-02-06 16:55:24+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,15393000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q3,2016-10-02,2016-12-31,2018-02-06 16:55:24+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,51708000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q3,2016-10-02,2016-12-31,2018-02-06 16:55:24+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.3
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q3,2016-10-02,2016-12-31,2018-02-06 16:55:24+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,52103000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q3,2016-10-02,2016-12-31,2018-02-06 16:55:24+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.3
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q3,2016-10-02,2016-12-31,2018-02-06 16:55:24+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,51300000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q3,2016-10-02,2016-12-31,2018-02-06 16:55:24+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.3
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q4,2017-01-01,2017-04-01,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,228066000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q4,2017-01-01,2017-04-01,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,228066000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q4,2017-01-01,2017-04-01,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,145955000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q4,2017-01-01,2017-04-01,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,145955000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q4,2017-01-01,2017-04-01,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,82111000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q4,2017-01-01,2017-04-01,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,71703000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q4,2017-01-01,2017-04-01,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,9321000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q4,2017-01-01,2017-04-01,,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,58593000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q4,2017-01-01,2017-04-01,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,139617000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q4,2017-01-01,2017-04-01,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,-57506000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q4,2017-01-01,2017-04-01,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1681000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q4,2017-01-01,2017-04-01,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1681000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q4,2017-01-01,2017-04-01,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,-59187000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q4,2017-01-01,2017-04-01,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,-8003000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q4,2017-01-01,2017-04-01,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-51184000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q4,2017-01-01,2017-04-01,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-51140000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q4,2017-01-01,2017-04-01,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-51140000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q4,2017-01-01,2017-04-01,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,51524000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q4,2017-01-01,2017-04-01,,,basiceps,Basic Earnings per Share,=,,usdpershare,-1.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q4,2017-01-01,2017-04-01,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,51524000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q4,2017-01-01,2017-04-01,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.99
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q4,2017-01-01,2017-04-01,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,51500000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2017.0,Q4,2017-01-01,2017-04-01,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-1.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q1,2017-04-02,2017-07-01,2018-08-07 16:06:38+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,210951000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q1,2017-04-02,2017-07-01,2018-08-07 16:06:38+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,210951000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q1,2017-04-02,2017-07-01,2018-08-07 16:06:38+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,119286000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q1,2017-04-02,2017-07-01,2018-08-07 16:06:38+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,119286000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q1,2017-04-02,2017-07-01,2018-08-07 16:06:38+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,91665000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q1,2017-04-02,2017-07-01,2018-08-07 16:06:38+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,66861000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q1,2017-04-02,2017-07-01,2018-08-07 16:06:38+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8193000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q1,2017-04-02,2017-07-01,2018-08-07 16:06:38+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,75054000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q1,2017-04-02,2017-07-01,2018-08-07 16:06:38+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,16611000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q1,2017-04-02,2017-07-01,2018-08-07 16:06:38+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,6641000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q1,2017-04-02,2017-07-01,2018-08-07 16:06:38+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,6641000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q1,2017-04-02,2017-07-01,2018-08-07 16:06:38+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,23252000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q1,2017-04-02,2017-07-01,2018-08-07 16:06:38+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,3100000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q1,2017-04-02,2017-07-01,2018-08-07 16:06:38+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,20152000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q1,2017-04-02,2017-07-01,2018-08-07 16:06:38+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,20137000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q1,2017-04-02,2017-07-01,2018-08-07 16:06:38+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,20137000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q1,2017-04-02,2017-07-01,2018-08-07 16:06:38+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,52443000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q1,2017-04-02,2017-07-01,2018-08-07 16:06:38+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.38
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q1,2017-04-02,2017-07-01,2018-08-07 16:06:38+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,52811000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q1,2017-04-02,2017-07-01,2018-08-07 16:06:38+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.38
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q1,2017-04-02,2017-07-01,2018-08-07 16:06:38+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,53000000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q1,2017-04-02,2017-07-01,2018-08-07 16:06:38+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.38
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q2,2017-07-02,2017-09-30,2018-11-06 16:22:21+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,225377000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q2,2017-07-02,2017-09-30,2018-11-06 16:22:21+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,225377000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q2,2017-07-02,2017-09-30,2018-11-06 16:22:21+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,120815000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q2,2017-07-02,2017-09-30,2018-11-06 16:22:21+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,120815000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q2,2017-07-02,2017-09-30,2018-11-06 16:22:21+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,104562000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q2,2017-07-02,2017-09-30,2018-11-06 16:22:21+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,72783000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q2,2017-07-02,2017-09-30,2018-11-06 16:22:21+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,7521000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q2,2017-07-02,2017-09-30,2018-11-06 16:22:21+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,80304000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q2,2017-07-02,2017-09-30,2018-11-06 16:22:21+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,24258000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q2,2017-07-02,2017-09-30,2018-11-06 16:22:21+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-1397000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q2,2017-07-02,2017-09-30,2018-11-06 16:22:21+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-1397000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q2,2017-07-02,2017-09-30,2018-11-06 16:22:21+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,22861000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q2,2017-07-02,2017-09-30,2018-11-06 16:22:21+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,2759000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q2,2017-07-02,2017-09-30,2018-11-06 16:22:21+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,20102000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q2,2017-07-02,2017-09-30,2018-11-06 16:22:21+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,20102000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q2,2017-07-02,2017-09-30,2018-11-06 16:22:21+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,20102000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q2,2017-07-02,2017-09-30,2018-11-06 16:22:21+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,52619000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q2,2017-07-02,2017-09-30,2018-11-06 16:22:21+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.38
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q2,2017-07-02,2017-09-30,2018-11-06 16:22:21+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,52981000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q2,2017-07-02,2017-09-30,2018-11-06 16:22:21+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.38
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q2,2017-07-02,2017-09-30,2018-11-06 16:22:21+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,52900000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q2,2017-07-02,2017-09-30,2018-11-06 16:22:21+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.38
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q3,2017-10-01,2017-12-30,2019-02-05 16:02:24+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,234043000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q3,2017-10-01,2017-12-30,2019-02-05 16:02:24+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,234043000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q3,2017-10-01,2017-12-30,2019-02-05 16:02:24+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,122748000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q3,2017-10-01,2017-12-30,2019-02-05 16:02:24+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,122748000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q3,2017-10-01,2017-12-30,2019-02-05 16:02:24+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,111295000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q3,2017-10-01,2017-12-30,2019-02-05 16:02:24+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,97855000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q3,2017-10-01,2017-12-30,2019-02-05 16:02:24+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,12427000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q3,2017-10-01,2017-12-30,2019-02-05 16:02:24+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,110282000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q3,2017-10-01,2017-12-30,2019-02-05 16:02:24+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,1013000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q3,2017-10-01,2017-12-30,2019-02-05 16:02:24+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-806000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q3,2017-10-01,2017-12-30,2019-02-05 16:02:24+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-806000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q3,2017-10-01,2017-12-30,2019-02-05 16:02:24+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,207000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q3,2017-10-01,2017-12-30,2019-02-05 16:02:24+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,6754000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q3,2017-10-01,2017-12-30,2019-02-05 16:02:24+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,-6547000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q3,2017-10-01,2017-12-30,2019-02-05 16:02:24+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,-6547000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q3,2017-10-01,2017-12-30,2019-02-05 16:02:24+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,-6547000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q3,2017-10-01,2017-12-30,2019-02-05 16:02:24+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,53090000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q3,2017-10-01,2017-12-30,2019-02-05 16:02:24+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,-0.12
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q3,2017-10-01,2017-12-30,2019-02-05 16:02:24+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,53090000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q3,2017-10-01,2017-12-30,2019-02-05 16:02:24+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,-0.12
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q3,2017-10-01,2017-12-30,2019-02-05 16:02:24+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,54600000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q3,2017-10-01,2017-12-30,2019-02-05 16:02:24+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,-0.12
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q4,2017-12-31,2018-03-31,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,233552000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q4,2017-12-31,2018-03-31,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,233552000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q4,2017-12-31,2018-03-31,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,129166000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q4,2017-12-31,2018-03-31,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,129166000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q4,2017-12-31,2018-03-31,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,104386000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q4,2017-12-31,2018-03-31,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,79024000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q4,2017-12-31,2018-03-31,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,11087000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q4,2017-12-31,2018-03-31,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,90111000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q4,2017-12-31,2018-03-31,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,14275000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q4,2017-12-31,2018-03-31,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-963000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q4,2017-12-31,2018-03-31,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-963000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q4,2017-12-31,2018-03-31,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,13312000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q4,2017-12-31,2018-03-31,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,1447000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q4,2017-12-31,2018-03-31,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,11865000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q4,2017-12-31,2018-03-31,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,11880000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q4,2017-12-31,2018-03-31,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,11880000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q4,2017-12-31,2018-03-31,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,52755000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q4,2017-12-31,2018-03-31,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.22
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q4,2017-12-31,2018-03-31,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,53501000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q4,2017-12-31,2018-03-31,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.21
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q4,2017-12-31,2018-03-31,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,53000000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2018.0,Q4,2017-12-31,2018-03-31,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.22
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q2,2018-07-01,2018-09-29,2019-11-01 16:06:36+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,241581000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q2,2018-07-01,2018-09-29,2019-11-01 16:06:36+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,241581000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q2,2018-07-01,2018-09-29,2019-11-01 16:06:36+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,129674000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q2,2018-07-01,2018-09-29,2019-11-01 16:06:36+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,129674000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q2,2018-07-01,2018-09-29,2019-11-01 16:06:36+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,111907000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q2,2018-07-01,2018-09-29,2019-11-01 16:06:36+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,77248000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q2,2018-07-01,2018-09-29,2019-11-01 16:06:36+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8583000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q2,2018-07-01,2018-09-29,2019-11-01 16:06:36+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q2,2018-07-01,2018-09-29,2019-11-01 16:06:36+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,85831000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q2,2018-07-01,2018-09-29,2019-11-01 16:06:36+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,26076000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q2,2018-07-01,2018-09-29,2019-11-01 16:06:36+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-3039000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q2,2018-07-01,2018-09-29,2019-11-01 16:06:36+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-3039000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q2,2018-07-01,2018-09-29,2019-11-01 16:06:36+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,23037000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q2,2018-07-01,2018-09-29,2019-11-01 16:06:36+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,4300000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q2,2018-07-01,2018-09-29,2019-11-01 16:06:36+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,18737000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q2,2018-07-01,2018-09-29,2019-11-01 16:06:36+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,18726000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q2,2018-07-01,2018-09-29,2019-11-01 16:06:36+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,18726000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q2,2018-07-01,2018-09-29,2019-11-01 16:06:36+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,51605000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q2,2018-07-01,2018-09-29,2019-11-01 16:06:36+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.36
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q2,2018-07-01,2018-09-29,2019-11-01 16:06:36+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,53138000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q2,2018-07-01,2018-09-29,2019-11-01 16:06:36+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.35
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q2,2018-07-01,2018-09-29,2019-11-01 16:06:36+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,52000000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q2,2018-07-01,2018-09-29,2019-11-01 16:06:36+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.36
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q3,2018-09-30,2018-12-29,2020-02-04 16:11:16+00:00,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,247356000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q3,2018-09-30,2018-12-29,2020-02-04 16:11:16+00:00,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,247356000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q3,2018-09-30,2018-12-29,2020-02-04 16:11:16+00:00,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,136181000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q3,2018-09-30,2018-12-29,2020-02-04 16:11:16+00:00,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,136181000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q3,2018-09-30,2018-12-29,2020-02-04 16:11:16+00:00,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,111175000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q3,2018-09-30,2018-12-29,2020-02-04 16:11:16+00:00,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,73877000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q3,2018-09-30,2018-12-29,2020-02-04 16:11:16+00:00,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8978000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q3,2018-09-30,2018-12-29,2020-02-04 16:11:16+00:00,totaloperatingexpenses,impairmentexpense,Impairment Charge,+,debit,usd,0.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q3,2018-09-30,2018-12-29,2020-02-04 16:11:16+00:00,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,82855000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q3,2018-09-30,2018-12-29,2020-02-04 16:11:16+00:00,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,28320000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q3,2018-09-30,2018-12-29,2020-02-04 16:11:16+00:00,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-2858000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q3,2018-09-30,2018-12-29,2020-02-04 16:11:16+00:00,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2858000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q3,2018-09-30,2018-12-29,2020-02-04 16:11:16+00:00,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,25462000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q3,2018-09-30,2018-12-29,2020-02-04 16:11:16+00:00,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,7185000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q3,2018-09-30,2018-12-29,2020-02-04 16:11:16+00:00,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,18277000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q3,2018-09-30,2018-12-29,2020-02-04 16:11:16+00:00,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,18277000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q3,2018-09-30,2018-12-29,2020-02-04 16:11:16+00:00,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,18277000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q3,2018-09-30,2018-12-29,2020-02-04 16:11:16+00:00,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,51401000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q3,2018-09-30,2018-12-29,2020-02-04 16:11:16+00:00,,basiceps,Basic Earnings per Share,=,,usdpershare,0.36
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q3,2018-09-30,2018-12-29,2020-02-04 16:11:16+00:00,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,52822000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q3,2018-09-30,2018-12-29,2020-02-04 16:11:16+00:00,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.35
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q3,2018-09-30,2018-12-29,2020-02-04 16:11:16+00:00,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,50800000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q3,2018-09-30,2018-12-29,2020-02-04 16:11:16+00:00,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.36
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q4,2018-12-30,2019-03-30,,totalrevenue,operatingrevenue,Operating Revenue,+,credit,usd,249295000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q4,2018-12-30,2019-03-30,,totalgrossprofit,totalrevenue,Total Revenue,+,credit,usd,249295000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q4,2018-12-30,2019-03-30,,totalcostofrevenue,operatingcostofrevenue,Operating Cost of Revenue,+,debit,usd,138085000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q4,2018-12-30,2019-03-30,,totalgrossprofit,totalcostofrevenue,Total Cost of Revenue,-,debit,usd,138085000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q4,2018-12-30,2019-03-30,,totaloperatingincome,totalgrossprofit,Total Gross Profit,+,credit,usd,111210000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q4,2018-12-30,2019-03-30,,totaloperatingexpenses,sgaexpense,"Selling, General & Admin Expense",+,debit,usd,78607000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q4,2018-12-30,2019-03-30,,totaloperatingexpenses,rdexpense,Research & Development Expense,+,debit,usd,8747000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q4,2018-12-30,2019-03-30,,totaloperatingincome,totaloperatingexpenses,Total Operating Expenses,-,debit,usd,87354000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q4,2018-12-30,2019-03-30,,totalpretaxincome,totaloperatingincome,Total Operating Income,+,credit,usd,23856000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q4,2018-12-30,2019-03-30,,totalotherincome,otherincome,"Other Income / (Expense), net",+,credit,usd,-2037000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q4,2018-12-30,2019-03-30,,totalpretaxincome,totalotherincome,"Total Other Income / (Expense), net",+,credit,usd,-2037000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q4,2018-12-30,2019-03-30,,netincomecontinuing,totalpretaxincome,Total Pre-Tax Income ,+,credit,usd,21819000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q4,2018-12-30,2019-03-30,,netincomecontinuing,incometaxexpense,Income Tax Expense,-,debit,usd,995000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q4,2018-12-30,2019-03-30,,netincome,netincomecontinuing,Net Income / (Loss) Continuing Operations,+,credit,usd,20824000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q4,2018-12-30,2019-03-30,,netincometocommon,netincome,Consolidated Net Income / (Loss),+,credit,usd,20835000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q4,2018-12-30,2019-03-30,,,netincometocommon,Net Income / (Loss) Attributable to Common Shareholders,=,credit,usd,20835000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q4,2018-12-30,2019-03-30,,basiceps,weightedavebasicsharesos,Weighted Average Basic Shares Outstanding,/,,shares,51533000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q4,2018-12-30,2019-03-30,,,basiceps,Basic Earnings per Share,=,,usdpershare,0.4
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q4,2018-12-30,2019-03-30,,dilutedeps,weightedavedilutedsharesos,Weighted Average Diluted Shares Outstanding,/,,shares,52942000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q4,2018-12-30,2019-03-30,,,dilutedeps,Diluted Earnings per Share,=,,usdpershare,0.39
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q4,2018-12-30,2019-03-30,,basicdilutedeps,weightedavebasicdilutedsharesos,Weighted Average Basic & Diluted Shares Outstanding,/,,shares,51400000.0
Haemonetics Corp,HAE,549300ZEL6TXZS6F5F95,0000313143,2019.0,Q4,2018-12-30,2019-03-30,,,basicdilutedeps,Basic & Diluted Earnings per Share,=,,usdpershare,0.4
